ASCO 2022 | NVG-111: a ROR1-targeting bispecific T-cell engager for CLL and MCL

Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College Hospital, London, UK, discusses the first-in-human Phase I study (NCT04763083) exploring a ROR1-targeting bispecific T-cell engager, NVG-111, in patients with relapse-refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) who had at least 2 prior systemic therapies and achieved partial or stable response to the last line of therapy. The main aim of this Phase I trial is to assess safety and efficacy and recommended Phase II dose. 6 patients were included, whereby 1 patient had cytokine response but did not demonstrate efficacy. 1 patient had undetectable minimal residual disease (MRD) in bone marrow and peripheral blood and another patient had low levels of MRD in bone marrow and none in peripheral blood. The other patients had detectable levels of MRD, however, experienced good reduction in disease levels. A manageable safety profile was demonstrated. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.